InMed Pharmaceuticals Inc. (IMLFF) to Present at the Canaccord Genuity 38th Annual...

 In Med Pharmaceuticals Inc. (Imlff) To Present At The Canaccord Genuity 38th Annual...

InMed to Present at the Canaccord Genuity 38th Annual Growth Conference

ÂInMed Pharmaceuticals Inc.Â(“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams , President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38thÂAnnual Growth Conference on August 8Âth, 2018, at 8:30 AM EST at the InterContinental Boston. The presentation will be available on InMed’s website. About InMed: InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid...



See Article on Marijuana Stocks HERE